Clinical observation of dapagliflozin in the treatment of heart failure combined with chronic kidney disease

YANG Zhiyun; ZHU Yongjun; CAI Feng; MA Hongyan; TIAN Aiying

doi:10.6039/j.issn.1001-0408.2024.20.12

您当前的位置：

首页 >

文章列表页 >

Clinical observation of dapagliflozin in the treatment of heart failure combined with chronic kidney disease

更新时间：2024-10-25

- Clinical observation of dapagliflozin in the treatment of heart failure combined with chronic kidney disease
- ZHONGGUO YAOFANG Vol. 35, Issue 20, Pages: 2512-2516(2024)
- 作者机构：
  
  1.商丘医学高等专科学校临床医学院，河南商丘　476000
  2.商丘市第一人民医院/商丘医学高等专科学校第一附属医院心内科，河南商丘　476100
  3.商丘市第一人民医院/商丘医学高等专科学校第一附属医院胃肠肝胆外科，河南商丘　476100
  4.商丘医学高等专科学校诊断学教研室，河南商丘　476000
  5.商丘市第一人民医院/商丘医学高等专科学校第一附属医院消化内科，河南商丘　476100
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.20.12
  CLC： R977.1+5
- Published：30 October 2024，
  
  Received：28 April 2024，
  
  Revised：29 August 2024，
- 稿件说明：
移动端阅览
杨志云,朱永军,蔡锋等.达格列净治疗心力衰竭合并慢性肾脏病的临床观察 ^Δ[J].中国药房,2024,35(20):2512-2516.

YANG Zhiyun,ZHU Yongjun,CAI Feng,et al.Clinical observation of dapagliflozin in the treatment of heart failure combined with chronic kidney disease[J].ZHONGGUO YAOFANG,2024,35(20):2512-2516.
杨志云,朱永军,蔡锋等.达格列净治疗心力衰竭合并慢性肾脏病的临床观察 ^Δ[J].中国药房,2024,35(20):2512-2516. DOI： 10.6039/j.issn.1001-0408.2024.20.12.

YANG Zhiyun,ZHU Yongjun,CAI Feng,et al.Clinical observation of dapagliflozin in the treatment of heart failure combined with chronic kidney disease[J].ZHONGGUO YAOFANG,2024,35(20):2512-2516. DOI： 10.6039/j.issn.1001-0408.2024.20.12.

摘要

目的

探讨达格列净对心力衰竭（HF）合并慢性肾脏病（CKD）患者心功能、肾功能、血糖、生活质量的影响及用药安全性。

方法

选择2021年1月1日至2023年1月1日商丘市第一人民医院收治的156例HF合并CKD患者，根据随机数字表法分为常规治疗组（

＝80）和达格列净组（

＝76）。常规治疗组患者给予常规治疗，达格列净组患者在常规治疗的基础上给予达格列净片10 mg，口服，每日1次。两组患者均治疗6个月。观察两组患者治疗前后的心功能[左室射血分数（LVEF）、左心室收缩末期内径（LVESD）、左心室舒张末期内径（LVEDD）、氨基末端脑利钠肽前体（NT-proBNP）

]

、肾功能[血肌酐、尿素氮、尿白蛋白排泄率（UAER）、肾小球滤过率（GFR）、肌酐清除率（CCR）

]

、糖化血红蛋白水平、生活质量，并记录不良反应发生情况。

结果

治疗后，两组患者的LVESD、LVEDD、NT-proBNP、血肌酐、尿素氮、UAER及达格列净组患者的糖化血红蛋白水平均显著低于同组治疗前，且达格列净组显著低于常规治疗组；LVEF、GFR、CCR、堪萨斯城心肌病问卷评分均显著高于同组治疗前，且达格列净组显著高于常规治疗组（

＜0.05）。常规治疗组患者治疗前后的糖化血红蛋白水平比较，差异无统计学意义（

＞0.05）。两组患者的头晕、皮疹、肝功能不全、泌尿系统感染、新发透析、低血压的发生率比较，差异均无统计学意义（

＞0.05）。

结论

达格列净能够改善HF合并CKD患者的心功能和肾功能，提高患者的生活质量，降低血糖水平，且未增加不良反应的发生风险。

Abstract

OBJECTIVE

To explore the effect and safety of dapagliflozin on cardiac function and renal function， blood glucose， and quality of life in patients with heart failure （HF） combined with chronic kidney disease （CKD）.

METHODS

A total of 156 patients with HF combined with CKD admitted to Shangqiu First People’s Hospital from January 1， 2021 to January 1， 2023 were included. According to the random number table， the patients were randomly divided into conventional treatment group （

＝80） and dapagliflozin group （

＝76）. Conventional treatment group was given conventional treatment； dapagliflozin group was additionally given Dapagliflozin tablets 10 mg orally， once a day， based on conventional treatment group. Both groups were treated for 6 months. Cardiac function [left ventricular ejection fraction （LVEF）， left ventricular end-systolic diameter （LVESD）， left ventricular end-diastolic diameter （LVEDD）， N-terminal pro-brain natriuretic peptide （NT-proBNP）

]

， renal function [blood creatinine， urea nitrogen， urinary albumin excretion rate （UAER）， glomerular filtration rate （GFR）， creatinine clearance rate （CCR）

]

， glycosylated hemoglobin， and the quality of life were observed in 2 groups before and after treatment. The occurrence of ADR was recorded.

RESULTS

After treatment， LVESD， LVEDD， NT-proBNP， blood creatinine， urea nitrogen， UAER in 2 groups as well as the level of glycosylated hemoglobin in dapagliflozin group were significantly lower than before treatment； the dapagliflozin group was significantly lower than the conventional treatment group. LVEF， GFR， CCR and Kansas City Cardiomyopathy Questionnaire score were significantly higher than before treatment， and the dapagliflozin group was significantly higher than the conventional treatment group （

＜0.05）. There was no statistical significance in glycosylated hemoglobin of conventional treatment group before and after treatment （

＞0.05）. There was no statistically significant difference in the incidence of dizziness， rash， liver dysfunction， urinary system infection， new dialysis and hypotension between the two groups （

＞0.05）.

CONCLUSIONS

Dapagliflozin can improve the cardiac function and renal function of patients with HF complicated with CKD， improve patients’ quality of life and lower blood sugar levels without increasing the risk of adverse events.

关键词

达格列净心力衰竭慢性肾脏病心功能肾功能安全性

Keywords

heart failurechronic kidney diseasecardiac functionrenal functionsafety

references

VIRANI S S，ALONSO A，BENJAMIN E J，et al. Heart disease and stroke statistics：2020 update：a report from the American Heart Association[J]. Circulation，2020，141（9）：e139-e596.

MATSUSHITA K，BALLEW S H，WANG A Y M，et al. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease[J]. Nat Rev Nephrol，2022，18（11）：696-707.

SZLAGOR M，DYBIEC J，MŁYNARSKA E，et al. Chronic kidney disease as a comorbidity in heart failure[J]. Int J Mol Sci，2023，24（3）：2988.

BRISCO M A，ZILE M R，HANBERG J S，et al. Relevance of changes in serum creatinine during a heart failure trial of decongestive strategies：insights from the DOSE trial[J]. J Card Fail，2016，22（10）：753-760.

GALLO L A，WRIGHT E M，VALLON V. Probing SGLT2 as a therapeutic target for diabetes：basic physio-logy and consequences[J]. Diab Vasc Dis Res，2015，12（2）：78-89.

中华医学会糖尿病学分会. 中国2型糖尿病防治指南：2020年版：上[J]. 中国实用内科杂志，2021，41（8）：668-695.

Diabetes Branch of Chinese Medical Association.Guideline for the prevention and treatment of type 2 diabetes mellitus in China：2020 edition：part 1[J]. Chin J Pract Intern Med，2021，41（8）：668-695.

HEIDENREICH P A，BOZKURT B，AGUILAR D，et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure：executive summary：a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. J Am Coll Cardiol，2022，79（17）：1757-1780.

射血分数保留的心力衰竭诊断与治疗中国专家共识制定工作组. 射血分数保留的心力衰竭诊断与治疗中国专家共识2023[J]. 中国循环杂志，2023，38（4）：375-393.

Chinese Expert Consensus Development Working Group on the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction. Diagnosis and treatment of heart failure with preserved ejection fraction：Chinese expert consensus 2023[J]. Chin Circ J，2023，38（4）：375-393.

MCDONAGH T A，METRA M，ADAMO M，et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J，2021，42（36）：3599-3726.

WEIR M R，LAKKIS J I，JAAR B，et al. Use of renin- angiotensin system blockade in advanced CKD：an NKF-KDOQI controversies report[J]. Am J Kidney Dis，2018，72（6）：873-884.

上海慢性肾脏病早发现及规范化诊治与示范项目专家组. 慢性肾脏病筛查诊断及防治指南[J]. 中国实用内科杂志，2017，37（1）：28-34.

Expert Group for Early Detection，Standardized Diagnosis and Treatment，and Demonstration Project of Chronic Kidney Disease in Shanghai. Guideline for screening， diagnosis，prevention and treatment of chronic kidney disease[J]. Chin J Pract Intern Med，2017，37（1）：28-34.

中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志，2018，46（10）：760-789.

Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association，Chinese Heart Failure Association of Chinese Medical Doctor Association，Editorial Board of Chinese Journal of Cardiology. China guidelines for diagnosis and treatment of heart failure 2018[J]. Chin J Cardiol，2018，46（10）：760-789.

YURISTA S R，SILLJÉ H H W，OBERDORF-MAASS S U，et al. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction[J]. Eur J Heart Fail，2019，21（7）：862-873

GORMSEN L C，SVART M，THOMSEN H H，et al. Ketone body infusion with 3-hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans：a positron emission tomography study[J]. J Am Heart Assoc，2017，6（3）：e005066.

MCMURRAY J J V，SOLOMON S D，INZUCCHI S E，et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med，2019，381（21）：1995-2008.

YOUNIS F，LEOR J，ABASSI Z，et al. Beneficial effect of the SGLT2 inhibitor empagliflozin on glucose homeostasis and cardiovascular parameters in the Cohen Rosenthal diabetic hypertensive（CRDH）rat[J]. J Cardiovasc Pharmacol Ther，2018，23（4）：358-371.

TAHARA A，TAKASU T. Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice[J]. Eur J Pharmacol，2018，830：68-75.

HEERSPINK H J L，STEFÁNSSON B V，CORREA-ROTTER R，et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med，2020，383（15）：1436-1446.

MCMURRAY J J V，WHEELER D C，STEFÁNSSON B V，et al. Effects of dapagliflozin in patients with kidney disease，with and without heart failure[J]. JACC Heart Fail，2021，9（11）：807-820.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Comparison of the efficacy and safety between the drug winning the bidding for centralized procurement and the original drug of ticagrelor in acute coronary syndrome patients after percutaneous coronary intervention

Clinical observation of bevacizumab combined with paclitaxel and carboplatin chemotherapy in the treatment of persistent or recurrent cervical cancer

Efficacy and safety of amphotericin B combined with posaconazole in the treatment of cryptococcal meningitis complicated with AIDS

Clinical observation of camrelizumab combined with pemetrexed and nedaplatin in the treatment of EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer

Clinical observation of venetoclax combined with homoharringtonine and cytarabine in the treatment of acute myeloid leukemia

Related Author

MIAO Yang

MENG Zhongru

QI Wang

ZHANG Dan

XU Kangshi

WANG Hongxia

ZHANG Liyi

JIANG Fengxi

Related Institution

Dept. of Cardiovascular Medicine， Yancheng First Hospital Affiliated of Nanjing University Medical School/Yancheng No. 1 People’s Hospital

Dept. of Pharmacy， Yancheng First Hospital Affiliated of Nanjing University Medical School/Yancheng No. 1 People’s Hospital

Dept. of Gynaecology and Obstetrics， Dazhou Central Hospital

Dept. of Pharmacy， the First Affiliated Hospital of Army Medical University

Dept. of Infection， Chongqing Public Health Medical Center

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰